Humanigen, Avid enter COVID-19 therapy manufacturing agreement

By The Science Advisory Board staff writers

February 3, 2021 -- Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigen's COVID-19 therapeutic candidate.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat cytokine storm associated with COVID-19. The candidate is currently in a phase III clinical trial in hospitalized COVID-19 patients.

Under the agreement, Avid will initiate technical transfer and analytical validation activities for lenzilumab with the goal of delivering current good manufacturing practice (cGMP) drug substance batches to support Humanigen's regulatory and potential commercial activities.

The agreement supports Humanigen's commercialization efforts for lenzilumab in advance of potential filings for emergency use authorization and a subsequent biologics license application later this year.

Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...
Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...
Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter